Lifeboat Foundation

Making the most of the low light in the muddy rivers where it swims, the elephant nose fish survives by being able to spot predators amongst the muck with a uniquely shaped retina, the part of the eye that captures light. In a new study, researchers looked to the fish’s retinal structure to inform the design of a contact lens that can adjust its focus.

Imagine a contact lens that autofocuses within milliseconds. That could be life-changing for people with presbyopia, a stiffening of the eye’s lens that makes it difficult to focus on close objects. Presbyopia affects more than 1 billion people worldwide, half of whom do not have adequate correction, said the project’s leader, Hongrui Jiang, Ph.D., of the University of Wisconsin, Madison. And while glasses, conventional contact lenses and surgery provide some improvement, these options all involve the loss of contrast and sensitivity, as well as difficulty with night vision. Jiang’s idea is to design contacts that continuously adjust in concert with one’s own cornea and lens to recapture a person’s youthful vision.

The project, for which Jiang received a 2011 NIH Director’s New Innovator Award (an initiative of the NIH Common Fund) funded by the National Eye Institute, requires overcoming several engineering challenges. They include designing the lens, algorithm-driven sensors, and miniature electronic circuits that adjust the shape of the lens, plus creating a power source — all embedded within a soft, flexible material that fits over the eye.

One of the latest inventions out of Tel Aviv University can patch up broken hearts. We’re talking about the real organs here, especially those damaged by myocardial infarction or heart attack. A team from the Israeli university created a “cyborg heart patch” that combines both living tissue and electronic components to replace the damaged parts of the organ. “It’s very science fiction, but it’s already here,” says one of its creators, Prof. Tal Dvir. “[W]e expect it to move cardiac research forward in a big way.” The patch can contract and expand like real heart tissue can, but it can do much, much more than that.

The electronic components allow doctors to remotely monitor their patients’ condition from afar. A physician could log into a computer and see if the implant is working as intended. If he senses that something’s amiss, he could release drugs to, say, regulate inflammation or fix the lack of oxygen. That sounds dangerous to us, since computers can be hacked. But the researchers are aiming to develop the patch further so it can regulate itself with no human intervention.

Dvir warns that the “practical realization of the technology may take some time.” For now, those suffering from cardiovascular diseases will have to rely on current treatment methods. The team is still in the midst of refining their cyborg heart patch. Plus, they’re looking at how to create bionic brain and spinal cord tissues using what they’ve learned so far to treat neurological conditions.

Continue reading “‘Cyborg heart patch’ combines electronics and living tissue” »

Finally there’s a use for dog drool: this spring, a new startup called Embark plans to launch a DNA testing kit for dogs that will tell owners about their canine’s ancestry, and disease risk. That’s not all the founders have in mind though; they may be aiming at human diseases by enlisting our longtime best friends.

Soon, interested pooch lovers will be able to swab their dogs’ slimy cheeks and mail in the sample. By extracting DNA from the swab, Embark’s founder says they’ll be able to trace a dog’s ancestry on a global level. The “Embark Dog DNA Test Kit” will also look for genetic variants that are associated with more than 100 diseases, and inform owners if their dog has a higher than average chance of developing one of them. The kit will also tell owners if their dog is likely to pass disease-associated mutations to a pup — which will likely be valuable information for breeders. Because of this, Embark’s founders say their product will be the most complete kit of its kind. At least, that’s the idea that Embark’s founders will be pitching today at SXSW.

For the company’s founders, the real objective will be the research they’ll be able to conduct with the DNA samples; that became clear when I spoke to two of Embark’s founders on the phone last week. They spent the first 10 minutes of the call talking about the potential of dog genetics to deliver advancements in human health. In fact, they were so enthusiastic about their future research that I had to interrupt them to steer the conversation back to the product we were supposed to discuss.

Continue reading “Doggie DNA startup wants to learn about human diseases from dog drool” »

A research team led by the University of Leeds has observed for the first time how HIV and Ebola viruses attach to cells to spread infection.

The findings, published today in the journal Angewandte Chemie (“Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions”), offer a new way of treating such viruses: instead of destroying the pathogens, introduce a block on how they interact with cells.

Continue reading “‘Sweet’ quantum dots light the way for new HIV and Ebola treatment” »

For Gartner and their Emerging Tech graph; may wish to rethink the biosensor being over 10 years away.

MicroRNAs are a newly discovered class of short (about 19 to 24 nuclides in length) fragments of noncoding RNAs that are useful biomarkers for diagnosing various diseases, including cardiac disease and some cancers. Since they are surprisingly well preserved in fluids such as urine and blood, their detection is well suited to a rapid, point-of-care method.

Mi Kyoung Park at the A*STAR Institute of Microelectronics and her co-workers have devised a silicon photonic biosensor that can detect tiny changes in the phase of a light beam caused by hybridization between an immobilized DNA probe and target microRNAs in a sample.

Continue reading “On-the-spot diagnosis of certain cancers with sensitive bionsensor” »

Polymers laden with chemotherapy drugs assemble at tumor cells and slip past their defenses.

A team of researchers at The Hong Kong Polytechnic University (PolyU) has designed a biosensor that uses an optical method called upconversion luminescence resonance energy transfer (LRET) for virus detection within 2–3 hours. Its cost is around HK$20 ($2.50) per sample—about 80% lower than traditional testing methods—and can be used for detecting different types of viruses, shedding new light on the development of low-cost, rapid, and ultrasensitive detection of different viruses.

Related: Infectious disease control with portable CMOS-based diagnostics

Traditional biological methods for flu virus detection include genetic analysis—reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) used in immunology. However, RT-PCR is expensive and time-consuming, while the sensitivity for ELISA is relatively low. Such limitations make them difficult for clinical use as a front-line and onsite diagnostic tool for virus detection.

Continue reading “Newly developed optical biosensor can detect viruses quickly and cheaply” »

Good news for MRIs; maybe witht he precision we also may not have to do any repeat scans as well.

Precision Glass & Optics recently announced the customization of two thin film optical components for a high-field magnetic resonance imaging (MRI) accessory. They developed the dielectric cold mirror and cylindrical prism mirror for the Real Eye Nano; an advanced visual presentation and eye-tracking system constructed of glass and plastic with a reduced size for operation in confined MRI spaces.

There are at least 200 forms of cancer and many more subtypes. Cancer is caused by an accumulation of DNA errors, or mutations, that allows cells to proliferate in an uncontrolled manner. Each cancer subtype has its own unique signature of DNA mutations in its genome; identifying these mutations and understanding how they interact to drive the disease is the foundation for improving cancer prevention, early detection and treatment.

TCGA’s finalized tissue collection contains matched tumor and normal tissues from 11,000 patients, and allows for the comprehensive characterization of 33 cancer types and subtypes, including 10 rare cancers. The comprehensive data that have been generated by TCGA’s network approach are freely available and widely used by the cancer community through the TCGA Data Portal and the Cancer Genomics Hub (CGHub).

In 2012, Cycle Computing and a multinational biotechnology company partnered to leverage cloud computing to analyze TCGA data in a unique way. The firm had developed a new end-to-end solution to identify DNA mutations in the TCGA data that could act as markers and risk factors in cancer samples. This solution included the typical SNP and DNA variation workflow, as well as a custom gene fusion, chromosome aberration discovery pipeline.

Continue reading “Leveraging Cloud Computing to Analyze Cancer Genome Atlas Data in a Unique Way” »